MedTrace Logo

Tau Imaging in Professional Fighters

NCT02278354 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2020-09-10

Study results available
· View outcomes & findings →

Summary

Subjects enrolled in the Professional Fighters Brain Health Study (PFBHS) will receive flortaucipir to explore its use as a biomarker for brain injury related to repetitive head trauma and to examine the relationship between clinical presentation and tau deposition.

Conditions

Interventions

DRUG

Flortaucipir F18

IV injection, 370 megabecquerel (MBq) (10 mCi)

PROCEDURE

Brain PET scan

positron emission tomography (PET) scan of the brain 75-105 minutes post injection

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • Avid Radiopharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-18
Primary Completion
2017-02-03
Completion
2017-02-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02278354 on ClinicalTrials.gov